DeCAF defines clinical fibroblast subtypes and multidimensional tumor-stroma crosstalk shaping prognosis and immunotherapy response - PubMed
3 days ago
- #Cancer-Associated Fibroblasts
- #Immunotherapy Response
- #Tumor Microenvironment
- DeCAF defines clinically significant cancer-associated fibroblast (CAF) subtypes: restraining (rest) and promoting (pro) CAFs.
- These CAF subtypes are prognostic and predictive of therapy response in multiple tumor types.
- Distinct interactions between pro- and restCAF subtypes and tumor subtypes support tumor-stroma crosstalk.
- restCAF-dominant tumors are more responsive to immune checkpoint inhibition, while proCAF-dominant tumors respond better to myeloid inhibition.
- A single-sample classifier, DeCAF, is developed for clinically actionable CAF subtype determination.
- Patent applications have been filed for the work, with PurIST covered by an issued patent.